Progression of chronic renal failure

Archives of Internal Medicine

Volumn 163, Issue 12, 2003, Pages 1417-1429

  Yu, Henry T ^a  

^a WJB Dorn VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN TYPE 4; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; FAS LIGAND; FIBRONECTIN; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAMININ; METOPROLOL; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BB; PROTEOGLYCAN; RAMIPRIL; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASOACTIVE AGENT;

BLOOD PRESSURE REGULATION; CELL INFILTRATION; CELL LOSS; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DNA POLYMORPHISM; DRUG ABUSE; DRUG UTILIZATION; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOXIA; KIDNEY CELL; KIDNEY FIBROSIS; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANOXIA; CELL DEATH; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RECEPTORS, ANGIOTENSIN; SMOKING;

EID: 0038339453     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.12.1417     Document Type: Review

References (273)

1. Coresh J, Wei L, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med. 2001;161:1207-1216.
2. Mitch WE, Walser M, Buffington GA, Lemann J Jr. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2:1326-1328.
3. Rutherford WE, Blondin J, Miller JP, Greenwalt AS, Vavra JD. Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int. 1977;11:62-70.
4. Muthusethupathi MA, Kumar SS, Sekaran L. Assessment of progression of chronic renal failure: using reciprocal of serum creatinine. J Assoc Physicians India. 1989;37:213-216.
5. Kirschbaum BB. Analysis of reciprocal creatinine plots in renal failure. Am J Med Sci. 1986; 291:401-404.
6. Rowe PA, Richardson RE, Burton PR, Morgan AG, Burden RP. Analysis of reciprocal creatinine plots by two-phase linear regression. Am J Nephrol. 1989;9:38-43.
7. Shah BV, Levey AS. Spontaneous changes in the rate of decline in reciprocal serum creatinine. J Am Soc Nephrol. 1992;2:1186-1191.
8. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease study. J Am Soc Nephrol. 1996;7:556-566.
9. Buckeit JB, Olshen RA, Blouch K, Myers BD. Modeling of progressive glomerular injury in humans with lupus nephritis. Am J Physiol. 1997; 273(1, pt 2): F158-F169.
10. Schainuck LI, Striker GE, Cutler RE, Benditt EP. Structural-functional correlations in renal disease, II: the correlations. Hum Pathol. 1970;1: 631-641.
11. Yarwood SJ, Woodgett JR. Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation. Proc Natl Acad Sci U S A. 2001;98: 4472-4477.
12. Ng YY, Huang TP, Yang WC, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney. Int. 1998;54:864-876.
13. Fan JM, Huang, XR, Ng, YY, et al. Interleukin-1 induces epithelial-myofibroblast transdifferentiation through a transforming growth factor-β1-dependent mechanism in vitro. Am J Kidney Dis. 2001;37:820-831.
14. Suzuki T, Kimura M, Asano M, Fujigaki Y, Hishida A. Role of atrophic tubules in development of interstitial fibrosis in microembolism-induced renal failure in rat. Am J Pathol. 2001;158:75-85.
15. Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int. 1999;56:1199-1207.
16. Savill JH. Regulation of glomerular cell number by apoptosis. Kidney Int. 1999;56:1216-1222.
17. Sugiyama H, Kashihara N, Maeshima Y, et al. Regulation of survival and death of mesangial cells by extracellular matrix. Kidney Int. 1998; 54:1188-1196.
18. Mooney A, Jackson K, Bacon R, et al. Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via β(1) integrin-mediated survival signals. Am J Pathol. 1999;155:599-606.
19. Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther. 2000;88: 333-347.
20. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993; 69:415-429.
21. Schelling JR, Cleveland RP. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int. 1999;56:1313-1316.
22. Schelling JR, Nkemere N, Kopp JB, Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest. 1998;78:813-824.
23. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest. 1999; 79:1089-1099.
24. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99: 342-348.
25. Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest. 2001;108:807-816.
26. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001;59: 2104-2113.
27. Isbel NM, Hill PA, Foti R, etal. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001;60:614-625.
28. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis: relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154:882-892.
29. Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987;31:964-972.
30. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 1995;48:753-760.
31. Yang N, Wu LL, Nikolic-Paterson DJ, et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 1998;13: 1967-1974.
32. Nakao A, Nosaka K, Ohishi N, et al. Long-term effects of LTB4 antagonist on lipid induced renal injury. Kidney Int Suppl. 1997;63:S236-S238.
33. Kang D, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model, I: potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001; 12:1434-1437.
34. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritis. Kidney Int 2001;60:167-172.
35. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93.
36. Kato H, Osajima A, Uezono Y, et al. Involvement of PDGF in pressure-induced mesangial cell proliferation through PKC and tyrosine kinase pathways. Aro J Physiol. 1999;277:F105-F112.
37. Suda T, Osajima A, Tamura M, et al. Pressure-induced expression of monocyte chemoattractant protein-1 through activation of MAP kinase. Kidney Int 2001;60:1705-1715.
38. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311:89-93.
39. Vora JP, Dolben J, Dean JD, et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992;41: 829-835.
40. Nelson RG, Tan M, Beck GJ, et al. Changing giomerular filtration with progression from impaired glucose tolerance to type II diabetes mellitus. Diabetologia. 1999;42:90-93.
41. Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications. 1995;9:304-307.
42. Imanishi M, Yoshioka K, Konishi Y, et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia. 1999;42:999-1005.
43. Stockand JD, Sansom SC. Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol Rev. 1998;78:723-744.
44. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348:101-108.
45. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet. 1992;340:807-810.
46. Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int. 1995;48:814-819.
47. Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW. Forty-five year follow-up after uninephrectomy. Kidney Int. 1993; 43:1110-1115.
48. Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR. Long-term follow-up after partial removal of a solitary kidney. N Engl J Med. 1991; 325:1058-1062.
49. Bohle A, Muller GA, Wehrmann M, Mackensen-Haen S, Xiao JC. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl. 1996;54:S2-S9.
50. Bohle A, von Gise H, Mackensen-Haen S, Stark-Jakob B. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli: functional interpretation of morphologic findings. Klin Wochenschr. 1981;59:1043-1051.
51. Zhu H, Bunn HF. Signal transduction: how do cells sense oxygen? Science. 2001;292:449-451.
52. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000;58:2351-2366.
53. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, Fine LG. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int. 1995;48:390-401.
54. Largo R, Gomez-Garre D, Soto K, et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension. 1999;33:732-739.
55. Mezzano SA, Barria M, Droguett MA, et al. Tubular NF-κB and AP-1 activation in human proteinuric renal disease. Kidney Int. 2001;60:1366-1377.
56. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis. 2001;37(suppl 2): S21-S24.
57. Wang S, Hirschberg R. Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol. 2000;278:F554-F560.
58. Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int. 2000;57:1002-1014.
59. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994;124:96-104.
60. Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor β1 and progression of renal failure. Kidney Int Suppl. 1997;63:S211-S214.
61. Niwa T, Tsukushi S, Ise M, et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein dietand oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997;23:179-184.
62. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl. 1997;62:S23-S28.
63. Aoyama I, Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats: Am J Kidney Dis. 2001;37(suppl 2):S7-S12.
64. Nankivell BJ, Boadle RA, Harris DCH. Iron accumulation in human chronic renal disease. Am J Kidney Dis. 1992;20:580-584.
65. Chen L, Zhang BH, Harris DC. Evidence suggesting that nitric oxide mediates iron-induced toxicity in cultured proximal tubule cells. Am J Physiol. 1998;274(1, pt 2):F18-F25.
66. Tang S, Lai KN, Chan TM, Lan HY, Ho SK, Sacks SH. Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. Am J Kidney Dis. 2001;37:94-103.
67. The GISEN Group (Gruppo Italiano di Studi Epidemiologic in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
68. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl. 2000; 75:S2-S6.
69. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984; 26:861-868.
70. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
71. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
72. Nomura A, Morita Y, Maruyama S, et al. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol. 1997;151:539-547.
73. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000;11:700-707.
74. Bentzel CJ. The filtered complement hypothesis [letter]. Kidney Int. 2000; 58:2597-2598.
75. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH. Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. J Am Soc Nephrol. 1999;10:69-76.
76. Harris RC, Cheng HF. The intrarenal renin-angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol. 1996;4:2-7.
77. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol. 1997;17:412-422.
78. Kennefick TM, Oyama TT, Thompson MM, Vora JP, Anderson S. Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol. 1996;271:F595-F602.
79. Verhagen AMG, Braam B, Boer P, Grone H-J, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int. 1999;56:222-231.
80. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, et al. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int. 2001;60:2153-2163.
81. Dussaule J, Tharaux P, Boffa J, Fakhouri F, Ardaillou R, Chatziantoniou C. Mechanisms mediating the renal profibrotic actions of vasoactive peptides in transgenic mice. J Am Soc Nephrol. 2000;11:S124-S128.
82. Yu XQ, Wu LL, Huang XR, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int. 2000; 58:1469-1480.
83. Gomez-Garre D, Largo R,Tejera N, FortesJ, Manzarbeitia F, Egido J. Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension. 2001;37:1171-1178.
84. Zeisberg M, Strutz F, Muller GA. Renal fibrosis: an update. Curr Opin Nephrol Hypertens. 2001; 10:315-320.
85. Gupta S, Clarkson MR, Duggan J, Brady HR. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000;58:1389-1399.
86. Wolf G, Aberle S, Thaiss F, et al. TNF alpha induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int. 1993;44:795-804.
87. Wolf G, Ziyadeh FN, Thaiss F, et al. Angiotensin II stimulates expression of the chemokine RANTEs in rat glomerular endothelial cells: role of the angiotensin type 2 receptor. J Clin Invest. 1997;100:1047-1058.
88. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A. 1999;96:10397-10402.
89. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol. 2001;280:F777-F785.
90. Wang SN, Lapage J, Hirschberg R. Glomerular ultrafiltrate and apical tubular actions of IGF-1, TGF-β, and HGF in nephrotic syndrome. Kidney Int. 1999;56:1247-1251.
91. Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG. Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int. 1995;48:45-51.
92. Taal MW, Zandi-Nejad K, Weening B, et al. Pro-inflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664-1676.
93. Ruger BM, Hasan Q, Erb KJ, Davis PF. Progression of renal disease in interleukin-4 transgenic mice: involvement of transforming growth factor-β. Int J Exp Pathol. 1999;80:113-123.
94. Floege J, Burns MW, Alpers CE, et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 1992;41:297-309.
95. Terzi F, Burtin M, Friedlander G. Using transgenic mice to analyze the mechanisms of progression of chronic renal failure. J Am Soc Nephrol. 2000;11:S144-S148.
96. Crook ED. Is there hope for preventing or slowing the progression of chronic renal disease? more support for the role of growth factors. Am J Kidney Ois. 2001;38:652-657.
97. Phillips AO, Topley N, Morrisey K, Williams JD, Steadman R. Basic fibroblast growth factor stimulates the release of pre-formed transforming growth factor-β1 from human proximal tubular cells in the absence of de-novo gene transcription or mRNA translation. Lab Invest. 1997; 76:591-600.
98. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int. 2001;59:2084-2094.
99. Miyajima A, Chen J, Lawrence C, et al. Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000;58:2301-2313.
100. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023-2038.
101. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix deposition by treatment with monodonal antitransforming growth factor β antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97:8015-8020.
102. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
103. Gesualdo L, Ranieri E, Monno R, et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int. 1999;56:461-470.
104. Krag S, Osterby R, Chai Q, Nielsen CB, Hermans C, Wogensen L. TGF-β1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest. 2000;80:1855-1868.
105. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
106. Sagripanti A, Morganti M, Carpi A, etal. Uremic medium increases cytokine-induced PAI-1 secretion by cultured endothelial cells. Biomed Pharmacother. 1998;52:298-302.
107. Rerolle J, Hertig A, Nguyen G, Sraer J, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000;58:1841-1850.
108. Arcos MI, Fujihara CK, Sesso A, et al. Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol. 2000;279:F1060-F1066.
109. Neugebauer S, Baba T, Watanabe T. Association of the nitric oxide synthase gene polymorphism with an increased risk for progression to diabetic nephropathy in type 2 diabetes. Diabetes. 2000;49:500-503.
110. Lau T, Owen W, Yu YM, et al. Arginine, citruiline, and nitric oxide metabolism in end-stage renal disease patients. J Clin Invest. 2000;105: 1217-1225.
111. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis: 2001; 38(4, suppl 1):S74-S79.
112. Goligorsky MS, Chen J, Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension. 2001; 37:744-748.
113. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000;58:1261-1266.
114. Schini VB, Durante W, Elizondo E, et al. The induction of nitric oxide synthase activity is inhibited by TGF-β1, PDGFAB and PDGFBB in vascular smooth muscle cells. Eur J Pharmacol. 1992;216:379-383.
115. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the remnant kidney. J Clin Invest. 1995; 96:953-964.
116. Markewitz BA, Michael JR, Kohan DE. Endothelin-1 inhibits the expression of inducible nitric oxide synthase. Am J Physiol. 1997;272(6, pt 1): L1078-L1083.
117. Ikeda M, Ikeda U, Ohkawa F, Shimada K, Kano S. Nitric oxide synthesis in rat mesangial cells induced by cytokines. Cytokine. 1994;6:602-607.
118. Berl T, Katz FH, Henric WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 1978;14:228-235.
119. Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21:98-101.
120. Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996;98:1063-1068.
121. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992;41:326-333.
122. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139.
123. Brown NJ, Nakamura S, Ma LJ, Nakamura I, Donnert E, Freeman M. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000;58:1219-1227.
124. Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232-237.
125. Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal artedopathy. Endocrinology. 2000;141:3871-3878.
126. Ballew JR, Fink GD. Role of endothelin ETB receptor activation in angiotensin II-induced hypertension: effects of salt intake. Am J Physiol Heart Circ Physiol. 2001;281:H2218-H2225.
127. Park JB, Schiffrin EL. ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37:1444-1449.
128. Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension. 1998;31:10-14.
129. Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 1998;54:353-359.
130. Wolf SC, Brehm BR, Gaschler F, et al. Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant. 1999;14 (suppl 4):29-30.
131. Ballew JR, Fink GD. Role of ETA receptors in experimental angiotensin II-induced hypertension in rats. Am J Physiol Regul Integr Comp PhysioL 2001;281:R150-R154.
132. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49:666-678.
133. Tang WW, Ulich TR, Lacy DL, et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial disease. Am J PathoL 1996;148: 1169-1180.
134. Tang WW, Van GY, Qi M. Myofibroblast and alpha 1(III) collagen expression in experimental tubulointerstitial nephritis. Kidney Int. 1997;51: 926-931.
135. Ostendorf T, Kunter U, Groene HJ, et al. Specific antagonism of PDGF prevents renal scaring in experimental glomerulonephritis. J Am Soc Nephrol. 2001;12:909-918.
136. Miziuri S, Hemmi H, Kumandomidou H, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int. 2001;60:1124-1130.
137. Navis G, van der Kleij FGH, de Zeeuw D, de Jong PE. Angiotensin-converting enzyme gene I/D polymorphism and renal disease. J Mol Med. 1999;77:781-791.
138. Hunley TE, Julian BA, Phillips JA III, et al. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int. 1996; 49:571-577.
139. Penno G, Chafurvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients. Diabetes. 1998;47:1507-1511.
140. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. Kidney Int. 2000;58:513-519.
141. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126-131.
142. Chuahirun T, Wesson DE. Smoking predicts faster progression of established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis. 2002;39:376-382.
143. Orth SR, Stockmann A, Conradt C, et al. Smoking is a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998; 54:926-931.
144. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis. 2000;35:687-694.
145. Halimi J, Giraudeau B, Vol S, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000;58:1285-1292.
146. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism. 1994;43:267-269.
147. Ritz E, Orth SR. Adverse effect of smoking on the renal outcome of patients with primary hypertension. Am J Kidney Dis. 2000;35:767-769.
148. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Muliple Risk Factor Intervention Trial. JAMA. 1992;268:3085-3091.
149. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277:1293-1298.
150. Hunsicker LG, Adler S, Gaggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908-1919.
151. Ergul S, Ergul A, Hudson JA, et al. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens. 1998;11(11, pt 1):1381-1385.
152. Suthanthiran M, Li B, Song JO, et al. Transforming growth factor-β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000;97:3479-3484.
153. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT: Multiple Risk Factor Intervention Trial. JAMA. 1997;278:2069-2074.
154. Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. Kidney Int. 1992;41:1311-1319.
155. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant. 1995; 10:1353-1360.
156. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51-CREDTA clearance. Kidney Int 1991;40:1050-1054.
157. Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S, Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998;13:1430-1437.
158. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329:85-89.
159. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995;25:515-533.
160. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Dpin Nephrol Hypertens. 2001;10:219-225.
161. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278-285.
162. Zdunek M, Silbiger S, Lei J, Neugarten J. Protein kinase CK2 mediates TGF-β1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int. 2001;60:2097-2108.
163. Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192-2196.
164. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11:669-683.
165. Oda H, Keane WF. Lipids in progression of renal disease. Kidney Int Suppl. 1997;62:S36-S38.
166. Attman PO, Samuelsson O, Alaupovic P. Progression of renal failure: role of apolipoprotein B-containing lipoproteins. Kidney Int Suppl. 1997; 63:S98-S101.
167. Stevenson FT, Shearer GC, Atkinson DN. Lipoprotein-stimulated mesangial cell proliferation and gene expression are regulated by lipoprotein lipase. Kidney Int. 2001;59:2062-2068.
168. Grone H, Hohbach H, Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl. 1996;54:S18-S22.
169. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293-301.
170. Washio M, Okuda S, Ikeda M, et al. Hypercholesterolemia and the progression of the renal dysfunction in chronic renal failure patients. J Epidemiol. 1996;6:172-177.
171. Yang WQ, Song NG, Ying SS, et al. Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci 1999;12:104-108.
172. Samuelsson O, Attman P, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998;9:1482-1488.
173. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997; 12:1908-1915.
174. Perneger TV, Klag MJ, Whelton PK. Recreational drug use: a neglected risk factor for endstage renal disease. Am J Kidney Dis. 2001;38: 49-56.
175. Norris KC, Thornhill-James M, Robinson C, et al. Cocaine use, hypertension, and end-stage renal diease. Am J Kidney Dis. 2001;38:523-528.
176. Lucas SR, Costa Silva VL, Miraglia SM, Zaladek Gil F. Functional and morphometric evaluation of offspring kidney after intrauterine undernutrition. Pediatr Nephrol. 1997;11:719-723.
177. Jones SE, Nyengaard JR, Flyvbjerg A, Bilous RW, Marshall SM. Birth weight has no influence on glomerular number and volume. Pediatr Nephrol. 2001;16:340-345.
178. Manalich R, Reyes L, Herrera M, Melendi C, Fundora I. Relationship between weight at birth and the number and size of renal glomeruli in humans: a histomorphometric study. Kidney Int. 2000;58:770-773.
179. Lackland DT, Egan BM, Fan ZJ, Syddall HE. Low birth weight contributes to the excess prevalence of end-stage renal disease in African Americans. J Clin Hypertens (Greenwich). 2001;3:29-31.
180. Hoy W, Kelly A, Jacups S, et al. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines. Aust N Z J Med. 1999;29:480-483.
181. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJ. Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med. 2000;160:1472-1476.
182. Law CM, de Swiet M, Osmond C, et al. Intiation of hypertension in utero and its amplication throughout life. BMJ. 1993;306:24-27.
183. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67.
184. Phillips DIW, Barker DJP, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37:150-154.
185. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulindependent diabetes, and end-stage renal disease. Am J Kidney Dis. 1995;25:350-356.
186. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69-75.
187. Garber SL, Mirochnik Y, Brecklin CS, et al. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 2001; 59:876-882.
188. Remuzzi G, Benigni A. Repairing renal lesions: will VEGF be the builder? Kidney Int. 2000;58: 2594-2595.
189. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 2001;37:677-688.
190. Klahr S, Levey A, Beck G, et al, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
191. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis. 1999;34:809-817.
192. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int. 2001;59:702-709.
193. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
194. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of Intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-1762.
195. Peterson JC, Adler SH, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995;123: 754-762.
196. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:1925-1930.
197. Imanishi M, Yoshioka K, Okumura M, et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int Suppl. 1997; 63:S198-S200.
198. Benigni A, Tomasoni S, Gagliardini E, et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol. 2001;12:941-948.
199. Macconi D, Ghilardi M, Bonassi ME, et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol. 2000;11:477-489.
200. Mifsud SA, Allen TJ, Bertram JF, et al. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 2001;44: 878-882.
201. Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int Suppl. 1997;63:S111-S114.
202. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol. 2000;279:F130-F143.
203. Sharma K, Eltayeb BO, McGowan TA, etal. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999;34:818-823.
204. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming-growth factor-β1 in humans. Am J Kidney Dis. 2000;36:894-902.
205. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-1462.
206. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
207. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuri. Lancet. 1999;354:359-364.
208. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Intern Med. 2001;134:370-379.
209. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160:2645-2650.
210. Agodoa LY, Appel MD, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized trial. JAMA. 2001;285:2719-2728.
211. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
212. Apperloo AJ, De Zeeuw D, De Jong PE. Short-term antiproteinuric response to antihypertensive reatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl. 1994;45:S174-S178.
213. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia. 2001;44:883-888.
214. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes,and hypertension. Diabetologia. 2001; 44:874-877.
215. Lewis, EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345:851-860.
216. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
217. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
218. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin: angiotensin system inpatients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ. 2000;321:1440-1444.
219. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20: 373-379.
220. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-769.
221. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis. 2002;39:159-164.
222. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38:18-25.
223. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int. 2001;59:2282-2289.
224. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels. Am J Kidney Dis. 2002;39:486-492.
225. Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 2 diabetes and microalbuminuria. Am J Kidney Dis. 2001;37:890-899.
226. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intem Med. 1996;125:201-204.
227. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-750.
228. Boero R, Rollino C, Massara C, et al. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol. 2001;14:15-18.
229. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650.
230. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-720.
231. Amann K, Koch A, Hofstetter J, et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int. 2001;60:1309-1323.
232. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
233. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol. 1999; 10:2426-2439.
234. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627-632.
235. Kasiske BL, Lakatua JDA, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954-961.
236. Walser M, Hill S. Can renal replacement be deferred by a supplemental very low protein diet? J Am Soc Nephrol. 1999;10:110-116.
237. Aparicio M, Chauveau P, Combe C. Are supplemented low-protein diets nutritionally safe? Am J Kidney Dis. 2001;37(suppl 2):S71-S76.
238. Clinical practice guidelines for nutrition in chronic renal failure: K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000;35(suppl 2):S1-S140.
239. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269.
240. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest. 1997;27:997-1002.
241. Kim SI, Kim HJ, Han DC, Lee HB. Effect of lovastatin on small GTP binding proteins and on TGF-β1 and fibronectin expression. Kidney Int Suppl. 2000;77:S88-S92.
242. Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001;59: 2095-2103.
243. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497-1499, A8.
244. Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149.
245. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451-458.
246. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926.
247. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999; 55:808-820.
248. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoletin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777-784.
249. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-185.
250. Roubicek C, Brunet P, Huiart L, et al. Timing of nephrology referral: influence on mortality and morbidity. Am J Kidney Dis. 2000;36:35-41.
251. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol. 1999;10:1281-1286.
252. Astor BC, Eustace JA, Powe NR, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis. 2001; 38:494-501.
253. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K. An economic evaluation of early versus late referral of patients with progressive renal insufficiency. Am J Kidney Dis. 2001;38: 1122-1128.
254. Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525-1532.
255. Taal MW, Nenov VD, Wong W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol. 2001;12:2051-2059.
256. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001;60:715-721.
257. Buckingham RE, Al-Barazanji KA, Toseland N, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47:1326-1334.
258. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001;59:1899-1910.
259. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-2139.
260. Boffa JJ, Tharaux PL, Dussaul JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001;37(pt 2):490-496.
261. Clozel M, Qiu C, Osterwalder R, et al. Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass. J Cardiovasc Pharmacol. 1999;33:611-618.
262. Terzi F, Burtin M, Hekmati M, et al. Targeted expression of a dominant negative epidermal growth factor receptor in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest. 2000;106:225-234.
263. Yang J, Dai C, Liu Y. Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. 2001;8:1470-1479.
264. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int. 2001;59:1304-1314.
265. Sebekova K, Paczek L, Dammrich J, et al. Effects of protease therapy in the remnant kidney model of progressive renal failure. Miner Electrolyte Metab. 1997;23:291-295.
266. Shimuzu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239-S243.
267. Throssell D, Brown J, Furness PN, Rutty G, Walls J, Harris KP. D-penicillamine reduces renal injury in the remnant model of chronic renal failure in the rat. Nephrol Dial Transplant. 1997;12: 1116-1121.
268. Hall AV, Parbtani A, Clark WF, et al. Abrogation of MRL/Ipr lupus nephritis by dietary flaxseed. Am J Kidney Dis. 1993;22:326-332.
269. Ingram AJ, Parbtani A, Clark WF, et al. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. Am J Kidney Dis. 1995;25:320-329.
270. Ogborn MR, Nitschmann E, Weiler H, Leswick D, Bankovic-Calic N. Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease. Kidney Int. 1999;55:417-423.
271. Maddox DA, Alavi FK, Silbernick EM, Zawada ET. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int. 2002;61:96-104.
272. Soroka N, Silverberg DS, Greemland M, et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron. 1998;79:173-180.
273. Velasquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis. 2001;37:1056-1068.